Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intellipharmaceutics International and Par Pharmaceutical have added the development and commercialization of additional strengths of generic Focalin XR (dexmethylphenidate hydrochloride) for the US market to their existing agreement.
Subscribe to our email newsletter
Focalin is used in the treatment of attention deficit hyperactivity disorder (ADHD).
Intellipharmaceutics will receive a cash amount from Par and will continue to obtain a share of profits from future sales, as per the agreement.
Intellipharmaceutics has a pending abbreviated new drug application (ANDA) with the FDA for five strengths (5, 10, 15, 20 and 30mg) of generic Focalin XR .
Intellipharmaceutics developes generic controlled-release and targeted-release oral solid dosage drugs with its patented Hypermatrix technology, a multidimensional controlled-release drug delivery platform.